CAMBRIDGE, England, June 19, 2015 /PRNewswire/ --
The fight against falsified medicines continues, with Aegate at the heart of many countries efforts to stop fake drugs and falsified medicines from reaching the patient.
Again the subject of fake drugs and counterfeit medicines is hitting the headlines across Europe. Today's article in a UK national newspaper highlights the shift of criminal gangs moving into the more lucrative area of fake diet pills, counterfeit cancer medicines and other fake drugs.
Aegate is at the forefront of the fight against falsified medicines, providing services to meet the requirements of the Falsified Medicines Directive, which all European countries will have to adopt and are some are already active in implementing. "Countries that have yet to move this forwards can and must act now to implement change and save lives," says Mark De Simone, CEO of Aegate. "The solution is here and now, and we have already scanned over 3 billion medicines in three European countries to provide the global market leading solution in the advance of patient safety"
"Some countries are moving forwards, as Romanian news TV showed last night, but others have yet to act," states Graham Smith, Commercial Director. He adds, "Aegate are continuing their information and education programme with the Aegate Safe Medicine Symposium in Frankfurt on 24-25th June."
With a documented history of some 3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 20,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices in Belgium, Italy, Switzerland and the UK. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real-time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Head of Marketing & Communications
Commercial Director Aegate Ltd
Cambridge Technology Centre
Melbourn SG8 6DP UK